化学免疫疗法
医学
抗体-药物偶联物
药品
免疫疗法
治疗指标
淋巴瘤
耐火材料(行星科学)
化疗
单克隆抗体
抗体
卡奇霉素
药理学
免疫学
癌症研究
肿瘤科
免疫系统
内科学
生物
天体生物学
作者
Hamza Hashmi,Alicia Darwin,Taiga Nishihori
标识
DOI:10.1016/j.hemonc.2021.07.002
摘要
Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy, especially in frail patients with advanced disease. Antibody drug conjugates represent a new class of novel targeted agents with significant improvement in therapeutic efficacy in the treatment of lymphomas. Several of these agents, which offer improved targeting, greater potency, and better therapeutic index over traditional chemotherapy, are changing the treatment landscape for lymphomas and other hematological malignancies. Despite the therapeutic potential of these agents, the delivery and release of cytotoxic agents to malignant cells through the combination of a monoclonal antibody, payload, and linker represents a complex design challenge. This article reviews the clinical data on currently available antibody drug conjugates and the ongoing development of novel antibody drug conjugates. Antibody drug conjugates constitute an important armamentarium for treatment of lymphomas and their evolving roles in the treatment spectrum are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI